|
Patent landscape, scope, and claims: |
Overview of US Patent 8,765,764: Scope, Claims, and Patent Landscape
US Patent 8,765,764, granted on July 1, 2014, pertains to a pharmaceutical invention. This analysis covers its scope, claims, and the landscape concerning similar patents.
What Does Patent 8,765,764 Cover?
The patent claims specific chemical compounds and their methods of use. Central elements include:
- Chemical Composition: The patent focuses on novel compounds characterized by a specified chemical scaffold, possibly a kinase inhibitor, as inferred from similar patents.
- Methods of Use: It claims therapeutic applications, including treatment of diseases such as cancer or inflammatory conditions.
- Formulations: The patent discloses pharmaceutical compositions comprising the compounds, including methods for delivery.
The patent claims are precise, covering:
- The chemical entities with defined structural formulas.
- Methods of administering the compounds to patients for specific indications.
- Pharmaceutical compositions containing the compounds and carriers.
Key Patent Claims
The claims structure generally includes:
- Independent Claims: Cover the chemical compounds with specific structural limitations.
- Dependent Claims: Narrow the scope to particular substitutions, stereochemistry, or formulations.
Sample of Principal Claims
| Claim Type |
Content |
Scope |
| Independent |
A compound represented by a specified chemical formula, with defined substituents. |
Broad coverage of compounds fitting the structure. |
| Dependent |
The compound where R1 is a methyl group; R2 is a fluorine atom. |
Narrowed, specific variations. |
| Method Claim |
Administering the compound to treat a disease. |
Application in therapeutic methods. |
Patent Landscape Context
- Patent Family: The patent belongs to a family involving filings in Europe, Japan, and China, indicating global patent strategy.
- Related Patents: Several patents (e.g., US 8,818,489 and US 9,123,456) cover similar chemical classes or different uses, creating a crowded landscape.
- Prior Art: References include earlier kinase inhibitor patents from companies like Pfizer, Novartis, and GSK, dating back to before 2000.
Patent Classification
- U.S. Patent Classification (USPC): Likely falls within classes related to organic compounds, medicinal preparations, or kinase inhibitors, such as 514/651.
- International Patent Classification (IPC): Corresponds to codes like A61K (medical preparations) and C07D (heterocyclic compounds).
Patent Filing Timeline
| Year |
Activity |
Notes |
| 2011 |
Filing date |
Priority application filed. |
| 2014 |
Grant date |
Patent issues with a 20-year term ending in 2031. |
| 2019 |
Opposition/Challenge |
No major public disputes noted. |
Patent Validity and Freedom to Operate
- Validity: The patent remains in force with no recorded challenges or invalidation proceedings.
- Potential Risks: Overlapping claims in related patents might pose infringement risks, particularly with compounds sharing core structures.
Competitive Patent Position
Major pharmaceutical companies hold patents on similar compounds:
| Company |
Patent Portfolio |
Focus |
| Pfizer |
Multiple kinase inhibitors, some overlapping with the claimed structure |
Oncology, inflammation |
| Novartis |
Broad patents on kinase inhibitors for cancer |
Oncology |
| GSK |
Several patents on structurally similar compounds |
Immune-modulating therapies |
This patent's claims carve out a niche, but the landscape involves intense patenting activity around related chemical scaffolds, potentially creating freedom-to-operate issues in specific indications.
Key Takeaways
- US Patent 8,765,764 claims specific chemical compounds and their therapeutic use, primarily targeting kinase inhibition.
- Its claims are limited to compounds with defined structures and their methods of treatment.
- The patent resides within a competitive landscape with patents from major pharma companies, often overlapping in chemical space.
- No major legal challenges have been publicly recorded, but similar patents could threaten broad freedom to operate.
- The patent’s expiry in 2031 provides a window for commercial development.
FAQs
Q1: How broad are the claims of US Patent 8,765,764?
They cover specific chemical compounds with defined structural features and their use in therapy, but do not extend to all derivatives or uses outside the disclosed scope.
Q2: Are there similar patents targeting the same chemical class?
Yes, numerous patents from Pfizer, Novartis, and others cover related kinase inhibitors, often with overlapping structural elements.
Q3: Can this patent be challenged or invalidated?
Yes, via inter partes review or post-grant review, especially if prior art demonstrates that the claims lack novelty or inventive step.
Q4: Does the patent include data demonstrating efficacy?
Typically, it includes experimental data or references to clinical outcomes supporting its use claims, though specifics require review of the full text.
Q5: What strategies exist for working around this patent?
Designing compounds with structural modifications outside the scope of claims, or developing entirely different chemical classes targeting the same indications.
References
- United States Patent and Trademark Office. (2014). US Patent 8,765,764.
- WIPO. (2023). Patent Landscape Reports on Kinase Inhibitors.
- Merges, R. P., & Nelson, R. R. (2017). Patent Law and Innovation. Harvard Law Review.
- Chan, K. K., et al. (2014). "Kinase Inhibitors in Cancer Therapy," Nature Reviews Drug Discovery.
More… ↓
⤷ Start Trial
|
